Full Year 2019 Hikma Pharmaceuticals PLC Earnings Call Transcript
So good morning, everyone. Welcome in this beautiful London weather. Just want to remind you, we are doing a webcast, so any conversation around the table will be heard around the world. So just keep the noise to a minimum around the table during the presentation.
And for the benefit of the people on the webcast, I'm Siggi Olafsson, the CEO of Hikma, and with me here today is Khalid Nabilsi, the CFO. I'm going to give you a quick update on the strategic progress we have made in Hikma, and then Khalid will take over and run through the financial results for 2019, outlook for 2020. And finally, we will open it up for questions and answers.
So 2019 has been another very good year for Hikma, with all our businesses performing well. Group delivered $2.2 billion in core revenue, up 6% over last year, demonstrating good organic growth. More importantly, this, combined with our focus on cost saving, is translating into a strong profitability with core operating profit up 10%. Across the group, we are really
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
